For the Inventor, By the Inventor

Enter assignee name

Rottapharm Spa

USPTO Granted Patents = 26

% Expired Patents = 57.7

CIPO Patents = 2

EPO Patents = 19

Trademarks = 1

Forward Citations = 34

Loading Chart...

Loading Chart...

38 inventors (with patents filed for the assignee):

Lucio C Rovati (20 out of 59 patents)

Francesco Makovec (17 out of 52 patents)

Antonio Giordani (16 out of 30 patents)

4. Gianfranco Caselli (10 out of 28 patents)

5. Stefano Mandelli (6 out of 9 patents)

6. Simona Zanzola (6 out of 9 patents)

7. Ilario Verpilio (4 out of 4 patents)

8. Andrea Zanardi (3 out of 3 patents)

9. Alessandra Cercaci (3 out of 3 patents)

10. Ivan Montaldo (3 out of 3 patents)

11. Roberto Artusi (3 out of 11 patents)

12. Massimo Maria D'Amato (3 out of 4 patents)

13. Francesca Tarchino (3 out of 3 patents)

14. Silvio Mazzari (3 out of 3 patents)

15. Joachim Maus (2 out of 11 patents)

26 patents: Sort by Forward Citations

1. 11998517 - Antimicrobial composition (2024-06-04),

2. 11234997 - Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments (2022-02-01),

3. 10912747 - Antimicrobial composition (2021-02-09),

4. 9623108 - Formulation for oral administration with beneficial effects on the cardiovascular system (2017-04-18),

5. 9174966 - Crystalline forms of 6-(1H-imidazol-1-yl)-2-phenylquinazoline (2015-11-03),

6. 9062129 - Hyaluronic acid esters, their preparation and use in dermatology (2015-06-23),

7. 8809306 - Combination andolast/glucocorticoids (2014-08-19),

8. 8633208 - 6-1H-imidazo-quinazoline and quinolines derivatives, new MAO inhibitors and imidazoline receptor ligands (2014-01-21),

9. 8420634 - Amidine, thiourea and guanidine derivatives of 2-aminobenzothiazoles and aminobenzothiazines for their use as pharmacological agents for the treatment of neurodegenerative pathologies (2013-04-16),

10. 8372866 - 2-aryl and 2-heteroaryl 4H-1-benzopyran-4-one-6-amidino derivatives, new pharmacological agents for the treatment of arthritis, cancer and related pain (2013-02-12),

11. 8258185 - Use of neboglamine in the treatment of toxicodependency (2012-09-04),

12. 8193353 - 6-1H-imidazo-quinazoline and quinolines derivatives, new potent analgesics and anti-inflammatory agents (2012-06-05),

13. 7994181 - 6-1H-imidazo-quinazoline and quinolines derivatives, new potent analgesics and anti-inflammatory agents (2011-08-09),

14. 7968558 - Amidine derivatives of 2-heteroaryl-quinazolines and quinolines; potent analgesics and anti-inflammatory agents (2011-06-28),

15. 7906551 - 3-substituted-1,5-diarly-2-alkyl-pyrroles highly selective and orally effective COX-2 inhibitors (2011-03-15),

Rottapharm is a pharmaceutical company focused on research, development, production, and marketing of innovative healthcare products. With a wide range of therapeutic areas, Rottapharm aims to improve the quality of life of patients by offering effective and safe treatments. Utilizing cutting-edge technology and scientific expertise, Rottapharm is dedicated to advancing medical knowledge and providing solutions to global health challenges.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

26 Patents

#71 in Milan

#358 in Italy

#24,735 in the World

Rottapharm Spa

Forward Citations = 34

38 inventors:

Lucio C Rovati (20 out of 59 patents)

Francesco Makovec (17 out of 52 patents)

Antonio Giordani (16 out of 30 patents)

4. Gianfranco Caselli (10 out of 28 patents)

5. Stefano Mandelli (6 out of 9 patents)

Please report any incorrect information to [email protected]

Loading…